argenx (ADR)
Develops antibody medicines for severe autoimmune diseases around the VYVGART franchise.
$1,023.21
After-hours close−0.20 (−0.02%)
At close$1,023.41(−3.35%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Jul 2026 | $6.27 | $7.32 | +16.7% |
| May 2026 | $6.08 | $5.90 | −3.0% |
| Oct 2025 | $4.37 | $5.18 | +18.5% |
| May 2025 | $0.98 | $2.58 | +163.3% |
The latest year is open to everyone — the 25 quarters behind it read with an account. Sign in | |||
| Mar 2025 | |||
| Oct 2024 | |||
| Sep 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Oct 2023 | |||
| Sep 2023 | |||
| Jun 2023 | |||
| May 2023 | |||
| Oct 2022 | |||
| Oct 2021 | |||
| May 2021 | |||
| Oct 2020 | |||
| May 2020 | |||
| Oct 2019 | |||
| May 2019 | |||
| Oct 2018 | |||
| May 2018 | |||
| Oct 2017 | |||
| May 2017 | |||
| Jun 2016 | |||
| Dec 2015 | |||
| Jun 2015 | |||
| Dec 2014 | |||
| Jun 2014 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Jul 23, 2026 | $6.27 | $7.32 | +16.7% | $1.63B | $2.82B | +72.7% |
| May 7, 2026 | $6.08 | $5.90 | −3.0% | $1.44B | $2.41B | +66.7% |
| Oct 30, 2025 | $4.37 | $5.18 | +18.5% | $1.28B | $948.0M | −25.7% |
| May 8, 2025 | $0.98 | $2.58 | +163.3% | $861.8M | $1.35B | +56.2% |
The latest year is open to everyone — the 25 quarters behind it read with an account. Sign in | ||||||
| Mar 31, 2025 | ||||||
| Oct 31, 2024 | ||||||
| Sep 30, 2024 | ||||||
| May 9, 2024 | ||||||
| Mar 31, 2024 | ||||||
| Oct 31, 2023 | ||||||
| Sep 30, 2023 | ||||||
| Jun 21, 2023 | ||||||
| May 4, 2023 | ||||||
| Oct 27, 2022 | ||||||
| Oct 28, 2021 | ||||||
| May 14, 2021 | ||||||
| Oct 22, 2020 | ||||||
| May 14, 2020 | ||||||
| Oct 24, 2019 | ||||||
| May 9, 2019 | ||||||
| Oct 25, 2018 | ||||||
| May 9, 2018 | ||||||
| Oct 26, 2017 | ||||||
| May 2, 2017 | ||||||
| Jun 30, 2016 | ||||||
| Dec 31, 2015 | ||||||
| Jun 30, 2015 | ||||||
| Dec 31, 2014 | ||||||
| Jun 30, 2014 | ||||||